stock-detail (PFE)

Oncology Corporate Profile

Company Description

This company does not have any commercial products

This company does not have any pipeline products

Recent News Headlines

FDA Warns Questionable Cancer Clinic Again for CGMP Violations

6/22/2016 02:00 pm

(Regulatory Affairs) June 21, 2016 - A little more than a month after the US Food and Drug Administration (FDA) was overruled by a judge to allow a college student with terminal cancer to re-start a clinical trial, in which he’s the only patient, FDA has issued a warning letter to the manufacturing facility linked to the trial, noting serious current good manufacturing practice (CGMP) violations.

Study Finds Patient Navigators Improve Comprehensive Cancer Screening Rates

6/21/2016 12:01 pm

(Mass General) June 20, 2016 - A clinical trial conducted by Massachusetts General Hospital (MGH) investigators has found that the use of patient navigators – individuals who assist patients in receiving health care services – may improve comprehensive cancer screening rates among patient populations not likely to receive recommended screenings.

Novartis Presents Data Showing Jakavi® Is Superior To Best Available Therapy In Patients With Less Advanced Polycythemia Vera (PV)

6/10/2016 12:00 pm

(Novartis) June 10, 2016 - Novartis today announced Phase III data from RESPONSE-2 showing that Jakavi® (ruxolitinib) helped patients with polycythemia vera (PV), who did not have an enlarged spleen and were resistant to or intolerant of hydroxyurea, achieve superior hematocrit control compared to best available therapy (BAT) at 28 weeks (62.2% vs 18.7%, respectively; p<0.0001).

Increased Testing Needed To Combat Rising Syphilis Infections

6/8/2016 12:00 pm

(USA Today) June 8, 2016 - As rates of syphilis infections in the United States continue to rise, doctors should increase screening for the disease among high-risk individuals, according to new recommendations from a government-backed health panel.

Myriad On Genetic Testing For Cancer Risk: Insurance Gap Is A ‘Crisis'

6/6/2016 02:02 pm

(Forbes) June 6, 2016 - Myriad is among several companies that are facing a headwind of resistance from, among others, the insurance industry, which has doubts about the value of testing so many genes.

Durvalumab Monotherapy Demonstrates Efficacy In Urothelial Bladder Cancer

6/5/2016 06:02 pm

(pharmiweb.com) June 5, 2016 - Data show objective response rate (ORR) of 31% in all evaluable patients and 46% in patients with PD-L1-high-expressing tumors.

Novel Daratumumab-Based Regimen Slows Multiple Myeloma Progression

6/5/2016 06:00 pm

(2016 ASCO Annual Meeting) June 5, 2016 – Initial findings from a pivotal phase III trial showed that daratumumab (DARZALEX) added to a standard two-drug regimen (bortezomib and dexamethasone) markedly improved outcomes for patients with recurrent or refractory multiple myeloma.

Ten Years of Hormone Therapy Reduces Breast Cancer Recurrence Without Compromising Quality of Life

6/5/2016 06:00 pm

(2016 ASCO Annual Meeting) June 5, 2016 - A randomized phase III clinical trial, MA.17R found that postmenopausal women with early breast cancer benefit from extending aromatase inhibitor (AI) therapy with letrozole (Femara) from 5 to 10 years.

Novartis Data Show More Than 50 Percent Of Eligible Ph+ CML Patients Maintain Treatment-free Remission (TFR) After Stopping Tasigna®

6/4/2016 05:03 pm

(Benzinga) June 4, 2016 - Novartis today announced at the 52nd American Society of Clinical Oncology (ASCO) Annual Meeting, the first results from the Tasigna (nilotinib) Treatment-free Remission (TFR) clinical trial program.

Juno Therapeutics’ Defined Composition CD19 Product Candidates Demonstrate Encouraging Clinical Outcomes and Tolerability

6/4/2016 05:03 pm

(Juno) June 4, 2016 - Durable remissions in adult ALL, NHL, and CLL patients with JCAR014; 100% complete molecular remission as measured by flow cytometry in pediatric ALL patients with JCAR017 and fludarabine/cyclophosphamide.

Amgen Receives Positive CHMP Opinion To Extend Indication Of Kyprolis® (Carfilzomib) For The Treatment Of Relapsed Multiple Myeloma

5/27/2016 10:02 am

(StreetInsider) May 27, 2016 - Amgen today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion to extend the current indication for Kyprolis® (carfilzomib) to include treatment in combination with dexamethasone alone for adult patients with multiple myeloma who have received at least one prior therapy.

NICE Turns Down Lilly's Lung Cancer Drug Portrazza

5/27/2016 06:05 am

(PharmaTimes [UK]) May 27, 2016 - The National Institute for Health and Care Excellence has published draft guidelines rejecting the drug, in combination with gemcitabine and cisplatin, for treating locally advanced or metastatic epidermal growth factor receptor (EGFR)-expressing squamous non-small-cell lung cancer that has not been treated with chemotherapy.

Sanofi Wins FDA Panel’s Backing for Once-Daily Diabetes Combo

5/26/2016 12:00 pm

(Bloomberg) May 25, 2016 - Sanofi’s once-a-day shot for diabetes that combines two drugs should be approved for sale, a group of advisers to the U.S. Food and Drug Administration said.

New Positive Phase III Study For Ner1006 - The First 1 Litre Peg-Based Bowel Preparation

5/25/2016 11:01 am

(Norgine) May 24, 2016 - Study met both primary endpoints demonstrating non-inferiority in overall bowel cleansing and superiority in ‘Excellent plus Good’ cleansing of the ascending colon.

Continuing Nivolumab Beyond Progression May Be Worthwhile in Kidney Cancer

5/20/2016 11:03 am

(Medscape Medical News/Reuters Health) May 19, 2016 - Nivolumab can be effective in patients with metastatic renal cell carcinoma (RCC) treated beyond first progression, according to a subgroup analysis of a phase 2 clinical trial.

Oncologists: Medicare Proposal Will Limit Cancer Patients’ Access to Drugs, Endanger Chances of Healing

5/18/2016 11:05 am

(cCARE) May 17, 2016 - A Medicare proposal for testing new ways to pay for drugs may jeopardize cancer patients’ health and chances of recovery, may also create two unequal classes of patients, and could further result in more patients being forced to seek costlier treatment in hospitals, says one of California’s largest private oncology practices.

Study Advances Understanding of Colon Cancer and Colitis

5/18/2016 11:04 am

(UC Riverside/UCR Today) May 17, 2016 - UC Riverside study explains how distribution of two forms of a transcription factor in the colon influence risk of disease.

JOP Editorial Examines Bundled Payment Approaches in Oncology, Proposes Inclusion of Value-based Pathways to Enhance System

5/13/2016 11:04 am

(ASCO in Action) May 12, 2016 - On May 12, the Journal of Oncology Practice (JOP) published an online editorial that examines bundled payment approaches in oncology and proposes the incorporation of a value-based pathways model to enhance the physician reimbursement system.

NHS England Reveals 'World-Class' Cancer Care Plans

5/12/2016 12:02 pm

(Daily Mail/Press Association [UK]) May 12, 2016 - People with a suspected case of cancer will be given a definitive diagnosis within four weeks under ambitious new plans to provide "world-class" cancer care in England.

AACR Congratulates Newest National Academy of Sciences Members

5/5/2016 11:04 am

(AACR) May 5, 2016 - The American Association for Cancer Research (AACR) congratulates its 10 members who have been elected to the National Academy of Sciences, including Fellows of the AACR Academy Anton Berns, PhD; Peter A. Jones, PhD, DSc; and Kenneth W. Kinzler, PhD.

New Treatment for Rare White Blood Cell Cancer

4/29/2016 11:01 am

(EMA) Apr 29, 2016 - The European Medicines Agency (EMA) has recommended extending the authorised indication of Gazyvaro (obinutuzumab) to treat patients with follicular lymphoma. The medicine is to be used in combination with bendamustine in patients who were previously treated with chemotherapy.

New Model Predicts Survival In Italian, Taiwanese with HCC

4/27/2016 11:05 am

(Healio) Apr 26, 2016 - Researchers recently developed the ITA.LI.CA prognostic system, which accurately predicted survival of Italian and Taiwanese patients with hepatocellular carcinoma, using data from the Italian Liver Cancer database. Further, the system may also serve as a potential use for designating treatment.

Tomosynthesis Beneficial for Dense, Nondense Breasts

4/27/2016 11:05 am

(Doctors Lounge/HealthDay News) Apr 26, 2016 - The addition of tomosynthesis to mammography is beneficial for women with dense and nondense breasts, and the readability of dense breast notifications vary by state, according to two research letters published in the April 26 issue of the Journal of the American Medical Association.

Cholesterol Levels, Not Statins, Influence Colorectal Cancer Risk, Penn Study Suggests

4/27/2016 11:04 am

(Penn Medicine) Apr 26, 2016 - Long-term use of the cholesterol-lowering drugs known as statins does not appear to decrease a patient's risk of colorectal cancer, suggests a new, large case-control study from Penn Medicine researchers published this week in PLOS Medicine.

Comparison of Three Different PD-L1 Diagnostic Tests Shows a High Degree of Concordance

4/18/2016 11:00 am

(AACR) Apr 18, 2016 - Three commercially available diagnostic tests were similarly effective in measuring PD-L1 protein expression on non-small cell lung cancer (NSCLC) tumor samples, indicating that health care providers may someday be able to use these tests interchangeably when determining which patients will respond best to anti-PD-L1/PD-1 immunotherapeutic drugs, according to research presented here at the AACR Annual Meeting 2016, April 16-20.